George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 290.00
Bid: 289.00
Ask: 293.00
Change: -14.00 (-4.61%)
Spread: 4.00 (1.384%)
Open: 312.00
High: 312.00
Low: 287.00
Prev. Close: 304.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

NOTIFICATION OF MAJOR HOLDINGS

1 Nov 2017 09:45

RNS Number : 2399V
Hutchison China Meditech Limited
01 November 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Hutchison China MediTech Limited;

Legal Entity Identifier: 2138006X34YDQ6OBYE79

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Voluntary disclosure

X

3. Details of person subject to the notification obligationiv

Name

Hutchison Healthcare Holdings Limited

City and country of registered office (if applicable)

British Virgin Islands

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

30/10/2017

6. Date on which issuer notified (DD/MM/YYYY):

30/10/2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

60.36%

60.36%

66,435,037

Position of previous notification (if

applicable)

60.36%

60.36%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares (KYG4672N1016) and American Depositary Shares (US44842L1035)

40,097,877

60.36%

SUBTOTAL 8. A

40,097,877

60.36%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

CK Hutchison Holdings Limited - indirect, but ultimate, owner of the shareholder

60.36%

60.36%

Hutchison Whampoa (China) Limited - direct owner of the shareholder and a subsidiary of CK Hutchison Holdings Limited

60.36%

60.36%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Voluntary notification following an offering of American Depository Shares by Hutchison China MediTech Limited.

 

Place of completion

Hong Kong

Date of completion

31 October 2017

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBBBLTMBJMMFR
Date   Source Headline
6th Jun 20197:00 amRNSDisclosure Update
31st May 20194:40 pmRNSSecond Price Monitoring Extn
31st May 20194:35 pmRNSPrice Monitoring Extension
29th May 201912:06 pmRNSResults of Extraordinary General Meeting
22nd May 201911:03 amRNSGrant of Share Options under Share Option Scheme
3rd May 20197:00 amRNSNotice of EGM & Shareholder Circular
24th Apr 20191:54 pmRNSResults of AGM
15th Apr 20197:30 amRNSDisclosure Update
15th Apr 20197:00 amRNSHK Listing Application - Proposed Global Offering
29th Mar 20197:00 amRNSStart of Phase IIb/III Surufatinib Trial in China
28th Mar 20197:30 amRNSSavolitinib Lung Cancer Presentations at AACR
25th Mar 20197:00 amRNSVesting of awards under Long Term Incentive Plan
21st Mar 20197:00 amRNSChi-Med 2018 Annual Report and Notice of AGM
11th Mar 201912:54 pmRNSPublication of Form 20-F
11th Mar 20197:00 amRNS2018 FY Results and Key Clinical Programs Update
12th Feb 20197:00 amRNSSavolitinib PRCC Data to be presented at ASCO GU
8th Feb 20197:00 amRNSChi-Med to Announce 2018 Final Results
7th Jan 20197:00 amRNSChi-Med Presents at JPM Healthcare Conference
31st Dec 20187:00 amRNSBlocklisting Six Monthly Return
31st Dec 20187:00 amRNSTotal Voting Rights
24th Dec 201812:41 pmRNSSecond Price Monitoring Extn
24th Dec 201812:36 pmRNSPrice Monitoring Extension
20th Dec 20187:13 amRNSChi-Med announce Savolitinib program update
20th Dec 20187:00 amRNSAmendment to Lilly Agreement on Fruquintinib
14th Dec 20187:21 amRNSTR-1: Form for notification of major holdings
30th Nov 20187:00 amRNSTotal Voting Rights
29th Nov 20188:00 amRNSChi-Med Enters into Multiple Collaborations
26th Nov 20187:00 amRNSFirst Commercial Launch of Fruquintinib Capsules
16th Nov 20187:00 amRNSPhase III FALUCA Trial Results for Fruquintinib
31st Oct 20187:00 amRNSTotal Voting Rights
22nd Oct 201810:05 amRNSGrant of Share Options under Share Option Scheme
18th Oct 20187:00 amRNSChi-Med Initiates a Ph I Trial of HMPL-523 for AML
5th Oct 20187:00 amRNSAppointment of HSBC Bank plc as Broker in London
5th Sep 20187:00 amRNSFruquintinib Approved for CRC in China
31st Aug 20187:00 amRNSTotal Voting Rights
7th Aug 201810:00 amRNSGrant of Share Options under Share Option Scheme
27th Jul 20187:00 amRNS2018 Interim Results and Clinical Programs Update
23rd Jul 20187:00 amRNSStart of Sulfatinib US Phase Ib/II PoC trial
29th Jun 20187:02 amRNSTotal Voting Rights
29th Jun 20187:01 amRNSBlocklisting Six Monthly Return
29th Jun 20187:00 amRNSChi-Med to Announce Half-Year Financial Results
7th Jun 201810:00 amRNSGrant of Share Options under Share Option Scheme
4th Jun 20189:41 amRNSFurther Fruquintinib FRESCO Trial Data - ASCO 2018
31st May 20187:00 amRNSTotal Voting Rights
30th Apr 20187:00 amRNSTotal Voting Rights
27th Apr 20181:52 pmRNSResults of Annual General Meeting
23rd Apr 20181:10 pmRNSGrant of Share Options under Share Option Scheme
23rd Apr 20181:05 pmRNSBlock Admission
29th Mar 20187:00 amRNSTotal Voting Rights
28th Mar 20187:00 amRNSVesting of awards under Long Term Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.